Altogether, this evidence supports that cysteamine may be an effective adjunct to antibiotic regimens for TB therapy, leading to a decreased bacterial load and inflammation due to its multiple capacities to inhibit TG2 and the NF-κB-mediated transcription of immune factors (25, 26, 57). The gene discussed is NFKB1; the disease is tuberculosis.